Figure 4From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyAssociation of HER2 and TOP2A relative mRNA expression (40-dCT values) with corresponding protein expression by IHC (A, B) and gene amplification by CISH (C, D). Comparisons were made using Kruskal Wallis and Mann-Whitney tests.Back to article page